TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9438438

Group type: EXPERIMENTAL
Intervention: Multislice (2D) single‐shot spiral scan technique
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multislice (2D) EPI scan technique
Number of subjects: 9

Group type: COMPARATOR
Intervention: 3D spiral scan technique
Number of subjects: 9
Study: 1514666

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 micrograms terbutaline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6209832

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy (venesection of 250‐650 ml during the first 2 days and low‐molecular weight dextran administration)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy
Number of subjects: 52
Study: 30938314

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass
Number of subjects: 0
Study: 29439736

Group type: EXPERIMENTAL
Intervention: Formula A (1.2 g/100 mL)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Formula B (1.7 g/100 mL)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Breastfed infants (reference group)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Formula A
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Formula B
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Formula A and B
Number of subjects: 118
Study: 26705066

Group type: EXPERIMENTAL
Intervention: Compression Sleeve (CS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kinesiology Tape (KT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 24748593

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) - 24 sessions for 3 days/week for 40 min at moderate intensity
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (Polymorphic group)
Number of subjects: 86
Study: 22561561

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (stable phase chronic obstructive pulmonary disease)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 40
Study: 20841644

Group type: EXPERIMENTAL
Intervention: Healthy Weight Assistant (HWA) web-based intervention for 12 weeks
Number of subjects: 297

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 297
Study: 18782802

Group type: EXPERIMENTAL
Intervention: Preservative-free artificial tears (Group 1)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Preservative-free artificial tears (Group 2)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Artificial tears containing a preservative (Group 3)
Number of subjects: 242
Study: 16670529

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis subsp. lactis BB‐12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Probiotics (AB‐Cap‐10)
Number of subjects: 29
Study: 12970245

Group type: EXPERIMENTAL
Intervention: Micromed DeBakey VAD®
Number of subjects: 150
Study: 10647066

Group type: EXPERIMENTAL
Intervention: Test diet with high soy protein and soluble fiber (12 +/- 2 g/d soy protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet with low-fat dairy and low-soluble-fiber foods
Number of subjects: 20
Study: 9296311

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8346486

Group type: EXPERIMENTAL
Intervention: WEB 2086 (100 mg three times a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3732901

Group type: EXPERIMENTAL
Intervention: 0.1 N hydrochloric acid infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1 N hydrochloric acid rechallenge
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1 N hydrochloric acid infusion in patients without duodenal ulcer
Number of subjects: 40
Study: 29546361

Group type: EXPERIMENTAL
Intervention: D3 + TL (Day 3 single embryo transfer with time-lapse hierarchical classification model)
Number of subjects: 600

Group type: COMPARATOR
Intervention: D5 + CM (Day 5 single embryo transfer with conventional morphological selection)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: D3 + TL
Number of subjects: 600

Group type: COMPARATOR
Intervention: D5 + CM
Number of subjects: 600
Study: 27876082

Group type: EXPERIMENTAL
Intervention: DAA‐facilitated single abstraction plus verification by a second person
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional (non‐DAA‐facilitated) single abstraction plus verification by a second person
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional independent dual abstraction plus adjudication
Number of subjects: 48
Study: 24160414

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21944168

Group type: EXPERIMENTAL
Intervention: High-intensity weight-lifting exercise and targeted multidisciplinary treatment
Number of subjects: 124
Study: 20485957

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (Ropi Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with epinephrine (Bupi Group)
Number of subjects: 30
Study: 19026891

Group type: EXPERIMENTAL
Intervention: 14.3% EDTA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SmearClear
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no smear layer removal procedure)
Number of subjects: 30
Study: 16078916

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12055582

Group type: EXPERIMENTAL
Intervention: Preoperative oral supplementation for 5 days with 1 L/day of a formula enriched with arginine, omega-3 fatty acids, and RNA (n = 102)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Preoperative oral supplementation plus postoperative jejunal infusion with the same enriched formula (n = 101)
Number of subjects: 305

Group type: COMPARATOR
Intervention: No artificial nutrition before and after surgery (conventional group; n = 102)
Number of subjects: 305
Study: 10606379

Group type: EXPERIMENTAL
Intervention: Topical 2% diclofenac in lecithin organogel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8695584

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg) administered at home 60 minutes before treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered at home 60 minutes before treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no diazepam or placebo)
Number of subjects: 25
Study: 2064345

Group type: COMPARATOR
Intervention: Tamoxifen (2x20 mg/day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Prednisolone (3x2.5 mg/day)
Number of subjects: 116
Study: 6677080

Group type: EXPERIMENTAL
Intervention: Two-year primary prevention program consisting of drug education, 'alternatives,' and affective in-service training for teachers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 30769293

Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with polymyxin B immobilized cartridge (DHP‐PMX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No DHP‐PMX therapy
Number of subjects: 0
Study: 29927273

Group type: EXPERIMENTAL
Intervention: Weight Watchers (WW)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Self-guided control (SG)
Number of subjects: 130
Study: 26771340

Group type: EXPERIMENTAL
Intervention: High eating frequency
Number of subjects: 115
Study: 25618970

Group type: EXPERIMENTAL
Intervention: Gushenyutai plaster plus comprehensive therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comprehensive therapy alone
Number of subjects: 62
Study: 21769610

Group type: EXPERIMENTAL
Intervention: Intention to reproduce learning in the future with self-controlled feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention to learn with low feedback schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention to learn with high feedback schedule
Number of subjects: 0
Study: 19207748

Group type: EXPERIMENTAL
Intervention: Waiting period of 30 min (Group I, n = 70)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No waiting period (Group II, n = 68)
Number of subjects: 138
Study: 17328070

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Azathioprine (AZA) plus Methylprednisolone (MP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both CYC and AZA
Number of subjects: 39
Study: 15239288

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5‐FU + leucovorin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 28
Study: 11559727

Group type: EXPERIMENTAL
Intervention: Surgical treatment by surgeons treating more than 10 cases
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Free radial margins
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Tumor adherence to adjacent structures
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: T and N classification
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Number and percentage of positive nodes
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 673
Study: 9717852

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per quality-adjusted life-year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision trees
Number of subjects: 0
Study: 7750185

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment skill of pause and regress in six parts
Number of subjects: 310

Group type: COMPARATOR
Intervention: Uniform reinforcing‐reducing method
Number of subjects: 310
Study: 2702881

Group type: EXPERIMENTAL
Intervention: Naloxone 40 micrograms/kg/hr
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 4210065

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 238
Study: 30113521

Group type: EXPERIMENTAL
Intervention: Minimalist shoe walking (MSW)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Foot strengthening (FS) exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 57
Study: 28279546

Group type: EXPERIMENTAL
Intervention: Green Dot intervention
Number of subjects: 89707

Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 89707
Study: 25214312

Group type: EXPERIMENTAL
Intervention: DaVinci robotic‐assisted laparoscopic prostatectomy (RARP)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Open radical retropubic prostatectomy (RRP)
Number of subjects: 255
Study: 23135774

Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg/kg within 0.9% saline solution)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25% in 0.9% saline solution)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 90
Study: 21989388

Group type: EXPERIMENTAL
Intervention: Combined stimulation of distant electrode contacts located in the subthalamic nucleus and caudal border zone of STN and substantia nigra pars reticulata [STN+SNr]
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional stimulation of the subthalamic nucleus [STNmono]
Number of subjects: 12
Study: 18497598

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sevoflurane (Control)
Number of subjects: 43
Study: 17174704

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI) strategy (NNRTI plus NRTI; n=463)
Number of subjects: 1397

Group type: COMPARATOR
Intervention: Protease inhibitor (PI) strategy (PI plus NRTI; n=470)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Three-class strategy (PI plus NNRTI plus NRTI; n=464)
Number of subjects: 1397

Group type: COMPARATOR
Intervention: Combined two-class strategies (NNRTI plus NRTI or PI plus NRTI)
Number of subjects: 1397
Study: 14601763

Group type: EXPERIMENTAL
Intervention: Sequential conditional probability ratio tests (SCPRTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCPRTs
Number of subjects: 0
Study: 10974295

Group type: EXPERIMENTAL
Intervention: Azithromycin (3‐day course, oral dose of 10 mg/kg per day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Topical oxytetracycline/polymyxin ointment (twice a day for 2 months)
Number of subjects: 96
Study: 8792795

Group type: EXPERIMENTAL
Intervention: Continuation of usual treatment (methotrexate, penicillamine, or sulfasalazine)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 1621750

Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg capsules twice a day or 15 mg/kg/day suspension)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Penicillin VK (250 mg capsules four times a day or 20 mg/kg/day suspension)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 107

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 107
Study: 7113952

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (mild) increasing daily expenditure to 110% of sedentary expenditure
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (moderate) increasing daily expenditure to 125% of sedentary expenditure
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sedentary treatment
Number of subjects: 6
Study: 31734761

Group type: EXPERIMENTAL
Intervention: Picosecond 1064-nm Nd:YAG laser (Pico-arm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Quasi-long-pulsed 1064-nm Nd:YAG laser (Quasi-arm)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pain assessment score (Pico-arm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pain assessment score (Quasi-arm)
Number of subjects: 25
Study: 31475793

Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2236

Group type: COMPARATOR
Intervention: Combination therapy with rivaroxaban plus a single antiplatelet agent
Number of subjects: 2236
Study: 27775865

Group type: EXPERIMENTAL
Intervention: Everolimus plus low-dose tacrolimus (EVR+LTac)
Number of subjects: 100
Study: 25895054

Group type: EXPERIMENTAL
Intervention: Responsive neurostimulator system (RNS System) for detecting ECoG events
Number of subjects: 128
Study: 23437144

Group type: EXPERIMENTAL
Intervention: 0.25 µg calcitriol per day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22128042

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care and attention control conditions
Number of subjects: 320
Study: 19150743

Group type: EXPERIMENTAL
Intervention: Standardized light breakfast (SLB) in adults with glucose intolerance (AD-GI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standardized light breakfast (SLB) in adults without glucose intolerance (AD-GT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fasting AG and AG/TG ratio in adults with glucose intolerance (AD-GI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fasting TG and AG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-SLB AG
Number of subjects: 32
Study: 17183010

Group type: EXPERIMENTAL
Intervention: School providing information on sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Easy communication with parent or guardian at baseline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low sexual health knowledge
Number of subjects: 0
Study: 15236979

Group type: EXPERIMENTAL
Intervention: Short hCG-IUI interval (32-34 hours)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Long hCG-IUI interval (38-40 hours)
Number of subjects: 189
Study: 12153554

Group type: EXPERIMENTAL
Intervention: Combined treatment with ursodeoxycholic acid (500 mg bid) and pravastatin (20 mg bid) for three weeks before cholecystectomy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid only
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined treatment with ursodeoxycholic acid and pravastatin
Number of subjects: 19
Study: 9817157

Group type: EXPERIMENTAL
Intervention: Current peak expiratory flow (PEF) criteria
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Sharpened cut-off values and time- and treatment-specific PEFs
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Morning peak expiratory flow before any (bronchodilator) treatment
Number of subjects: 133
Study: 7543891

Group type: EXPERIMENTAL
Intervention: High dose rate (HDR) conformal boost brachytherapy with 45.6 Gy whole pelvis external irradiation and three HDR fractions of 5.5 Gy each (18 patients) or 6 Gy each (15 patients) to the prostate.
Number of subjects: 33
Study: 2708231

Group type: EXPERIMENTAL
Intervention: Inhaled lipopolysaccharides (LPS) from Escherichia coli 026:B6 (22.2-micrograms total dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo procedure (diluent substituted for LPS solution)
Number of subjects: 14
Study: 322922

Group type: COMPARATOR
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 10
Study: 31635952

Group type: EXPERIMENTAL
Intervention: Cough management algorithm
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 115
Study: 28218605

Group type: EXPERIMENTAL
Intervention: GSS6Fr (6 Fr Glidesheath Slender)
Number of subjects: 1926

Group type: COMPARATOR
Intervention: GS5Fr (standard 5 Fr sheath)
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Patent haemostasis
Number of subjects: 1926

Group type: COMPARATOR
Intervention: Institutional haemostasis
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Secondary endpoints (vascular access-site complications, local bleeding, spasm)
Number of subjects: 1926
Study: 24833003

Group type: EXPERIMENTAL
Intervention: Liberal blood glucose management (BGM) (120-180 mg/dl)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Strict blood glucose management (BGM) (90-110 mg/dl)
Number of subjects: 846
Study: 23829604

Group type: COMPARATOR
Intervention: Elite female football players (ET)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Untrained young women (UT) after 16 weeks of football training
Number of subjects: 55
Study: 21771085

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS mixture (8 g/l)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 74
Study: 18706874

Group type: EXPERIMENTAL
Intervention: GERD (defined as heartburn and/or regurgitation of any frequency during the 1-week recall period of the RDQ)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: GERD
Number of subjects: 1200
Study: 17196507

Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 15234686

Group type: EXPERIMENTAL
Intervention: Normal subjects (no TMJ-ID)
Number of subjects: 6

Group type: COMPARATOR
Intervention: TMJ-ID subjects (with anterior disc displacement)
Number of subjects: 6
Study: 12127031

Group type: EXPERIMENTAL
Intervention: Cooling with 8 degrees C for 30 min on the burn
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-active dummy on the control burn
Number of subjects: 24
Study: 9747475

Group type: EXPERIMENTAL
Intervention: Trials in rhinology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trials in head and neck oncology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall RCTs assessed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reporting of RCTs in ENT literature
Number of subjects: 0
Study: 7966789

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy with M‐VAC or M‐VEC
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Adjuvant M‐VAC/M‐VEC
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 83
Study: 2752698

Group type: EXPERIMENTAL
Intervention: Dyazide (triamterene 50 mg and hydrochlorothiazide 25 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Generic triamterene-hydrochlorothiazide product
Number of subjects: 30
Study: 331919

Group type: EXPERIMENTAL
Intervention: Cyclandelate (1200 mg daily) plus amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither placebo nor cyclandelate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31475391

Group type: EXPERIMENTAL
Intervention: NBO education programme
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no NBO education)
Number of subjects: 111
Study: 29553435

Group type: EXPERIMENTAL
Intervention: Oral rehydration salts plus Zn sulphate (10 mg for children younger than 6 months; 20 mg for children aged 6 months and older)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral rehydration salts plus Zn sulphate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral rehydration salts
Number of subjects: 140
Study: 27439082

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention: structured moderate-intensity program, predominantly walking 2 times per week for 2.6 years on average.
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Successful aging intervention: weekly health education sessions for 6 months, then monthly.
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Successful aging intervention
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention among frailer participants (SPPB < 8)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Successful aging intervention among frailer participants (SPPB < 8)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention among participants with SPPB score of 8 or 9
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Successful aging intervention among participants with SPPB score of 8 or 9
Number of subjects: 1635